Profil bibliographique

Joanna Truelove

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

46Publications signalées

14Citations signalées

0Affiliations récentes

Les domaines associés

PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatmentRadio Frequency Integrated Circuit DesignCancer Genomics and Diagnostics

Les publications récentes

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Liquid biopsy time points.

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Functional homologous recombination repair.

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S1. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Kaplan Meier curves.

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Methodology 1 from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Supplementary Methodology.

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S4. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Cell-free circulating DNA copy-number profiles.

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Table S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Liquid biopsy time points.

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figure S5. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

BRCA2 reversion mutation detected in cell-free circulating DNA from patient 16.

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Table S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Progression-free survival according to functional homologous recombination repair and somatic copy-number alteration status.

0 citations

Accès ouvert 2023 other OpenAlex

Data from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

AbstractPurpose: A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2-mutant high-grade serous ovarian cancer (gBRCAm-HGSOC). The feasibility of a second maintenance course of PARPi was unknown. Patients and Methods: Phase II trial with two entry …

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figure S4. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Cell-free circulating DNA copy-number profiles.

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figure S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Cell-free circulating DNA yields at each time point.

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figure S1. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Robert David Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price et autres

Kaplan Meier curves.

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.